Periodontal disease in a patient receiving Bevacizumab: a case report
<p>Abstract</p> <p>Introduction</p> <p>Bevacizumab is a monoclonal antibody that inhibits the action of vascular endothelial growth factor (VEGF) thereby acting as an angiogenesis inhibitor. As a result, supply of oxygen and nutrients to tissues is impaired and tumour c...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2008-02-01
|
| Series: | Journal of Medical Case Reports |
| Online Access: | http://www.jmedicalcasereports.com/content/2/1/47 |